Patents by Inventor John J. Taggart

John J. Taggart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
    Patent number: 8058282
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: November 15, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY
    Publication number: 20110046109
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: August 19, 2010
    Publication date: February 24, 2011
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • NOVEL COMPOUNDS
    Publication number: 20110009625
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: September 16, 2010
    Publication date: January 13, 2011
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • 2,4,5-Trisubstituted pyrimidine compounds
    Patent number: 7759486
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: August 16, 2007
    Date of Patent: July 20, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • Compounds
    Patent number: 7700768
    Abstract: Novel substituted pyrimido[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: April 20, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, John J. Taggart, Ralph F. Hall
  • Tetrasubstituted pyrimidine compounds as chemical intermediates
    Patent number: 7629462
    Abstract: Novel substituted pyrimido[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: December 8, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, John J. Taggart, Ralph F. Hall
  • MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS
    Publication number: 20090258858
    Abstract: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
    Type: Application
    Filed: October 28, 2005
    Publication date: October 15, 2009
    Inventors: Jakob Busch-Petersen, Jeffrey Charles Boehm, Huijie Li, John J. Taggart, Hong Xing Yan
  • Novel Compounds
    Publication number: 20090137550
    Abstract: This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N?-substituted-N?-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: March 24, 2006
    Publication date: May 28, 2009
    Inventors: Jeffrey C. Boehm, John J. Taggart
  • NOVEL COMPOUNDS
    Publication number: 20090105478
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: August 16, 2007
    Publication date: April 23, 2009
    Inventors: JERRY L. ADAMS, JEFFREY C. BOEHM, RALPH HALL, QI JIN, JIRI KASPAREC, DOMINGOS J. SILVA, JOHN J. TAGGART
  • Novel compounds
    Publication number: 20090048442
    Abstract: Novel substituted pyrimido[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: October 11, 2007
    Publication date: February 19, 2009
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, John J. Taggart, Ralph F. Hall
  • Novel Compounds
    Publication number: 20090005401
    Abstract: This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N?-substituted-N?-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 15, 2008
    Publication date: January 1, 2009
    Inventors: Jeffrey C. Boehm, John J. Taggart
  • Novel Process and Formulations
    Publication number: 20080268044
    Abstract: The present invention provides for a novel process of making 6-carboxylic acid derivatives of pyrido[2,3-d]pyrimidin-7-one's, as well as a novel process for making 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-{[2-hydroxy-1-(hydroxymethyl)ethyl]-amino}pyrido[2,3-d]pyrimidin-7(8H)-one, and salts thereof.
    Type: Application
    Filed: November 15, 2006
    Publication date: October 30, 2008
    Inventors: John Robert George Appleby, Philip Blatcher, Ann M. Diederich, Lesley Anne Humphries, Jiri Kasparec, As'ad Abu Khalil, Richard S. Lloyd, Paul G. Spoors, John J. Taggart, Lois E. Vernon
  • Chemical Compounds
    Publication number: 20080269291
    Abstract: The invention is directed to novel indolecarboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): where R1, R2, R3 and X are defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).
    Type: Application
    Filed: November 17, 2006
    Publication date: October 30, 2008
    Inventors: Jeffrey K. Kerns, Jakob Busch-Petersen, Huijie Li, Jeffrey Charles Boehm, Hong Nie, John J. Taggart
  • Compounds
    Patent number: 7423042
    Abstract: This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N?-substituted-N?-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: September 9, 2008
    Assignee: Glaxo Group Limited
    Inventors: Jeffrey C. Boehm, John J. Taggart
  • 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds
    Patent number: 7323472
    Abstract: The present invention is directed to the novel use of a CSBP/p38 inhibitor for the treatment, including prophylaxis of inflammation enhanced cough in a mammal in need thereof.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: January 29, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds
    Patent number: 7314881
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: January 1, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates
    Patent number: 7314934
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: January 1, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
    Patent number: 7235551
    Abstract: Novel substituted pyrimidol[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: June 26, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, John J. Taggart, Ralph F. Hall
  • Novel compounds
    Publication number: 20040209901
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: April 6, 2004
    Publication date: October 21, 2004
    Applicant: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • Novel compounds
    Publication number: 20040116697
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: April 18, 2003
    Publication date: June 17, 2004
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart